In this online CME self-learning program:
Inflammatory bowel disease (IBD) is a broad term that includes many different forms of inflammatory bowel conditions, the most common of which are Crohn’s disease and ulcerative colitis (UC). Crohn’s disease affects any area of the alimentary canal, whereas ulcerative colitis is limited to the rectum and colon. Guidelines exist for the treatment of IBD, but they are constantly changing to include updated information. The World Gastroenterology Organization, for example, published updated practice guidelines in 2010 for IBD including extensive diagnosis and treatment criteria. The American College of Gastroenterology published updated practice guidelines in 2010 for ulcerative colitis and in 2009 for Crohn’s disease. The National Institute for Health and Clinical Excellence (NICE) released treatment guidelines for Crohn’s disease in 2013.Finally, NICE has provided much more recent clinical guidance and quality standards in 2015. Research suggests that healthcare professionals are oftentimes unable to keep up with the steady publishing of literature and evolution of clinical practice, continuing education learning activities in this area are warranted.
Agenda:
Introduction, Disclosures |
Epidemiology of and risk factors for IBD
|
Diagnostic pearls
|
Updates in the pharmacotherapy of IBD
|
Barriers to optimal care in patients with IBD [Learning Objective #5]
|
Summary, conclusions, and best practice recap |
Healthcare professionals specializing in: gastroenterology, primary care, and those who otherwise commonly care for or clinically encounter patients with IBD.
This program is supported by an educational grant from SHIRE and VALEANT
Release Date: January 30, 2016 -- Expiration Date: January 30, 2018
Faculty: Raymond Cross, M.D., M.S., AGAF
By the end of the session the participant will be able to:
ACCREDITATION HAS EXPIRED. NO CERTIFICATES WILL BE ISSUED.
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.
Faculty Disclosure: Raymond Cross, MD has received grant funding and/or is a consultant for Abbvie, Janssen, Shire, Takeda, and UCB.
Disclosures of Educational Planners: Charles Turck, PharmD is an officer and part owner of ScientiaCME, LLC.
Commercial Support Disclosure: This program is supported by an educational grant from SHIRE and VALEANT
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.